Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Tylosin: adverse event reports

All products with this active ingredient · 7 FDA-approved applications in the Green Book

1,184reports naming this ingredient, 1987–20260.1% of all reports · about 30 a year
27reports, 12 months to March 202631 in the 12 months before
45.2%classed serious, as reportedof 279 reports stating it
21.5%record death or euthanasia, as reported254 reports
24%of reports concern dogs0% of all dog reports

Between June 1987 and March 2026 FDA received 1,184 adverse event reports listing a drug with tylosin as the recorded active ingredient. The Green Book lists 7 FDA-approved applications with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 27 reports named it, down 13% from 31 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 30 reports a year and 0.1% of all 1,357,245 reports (0% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed death (14.9%), accidental exposure (14%) and lack of efficacy (bacteria) - NOS (13.4%). A report can list several signs, so shares add to more than 100%; 630 different terms appear across these reports.

24% of reports concern dogs. Not every report describes illness: 11.7% as product or packaging defects. Of reports that state seriousness, 45.2% were classed as serious, and 21.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog86 · peak 5
May 2021: 2Jul 2021: 1Aug 2021: 4Jan 2022: 1Mar 2022: 3Apr 2022: 3May 2022: 1Jul 2022: 2Jan 2023: 2Feb 2023: 5Apr 2023: 1May 2023: 3Jul 2023: 2Aug 2023: 1Sep 2023: 1Oct 2023: 1Nov 2023: 5Dec 2023: 3Jan 2024: 2Feb 2024: 2Mar 2024: 4Apr 2024: 4May 2024: 1Aug 2024: 1Sep 2024: 4Oct 2024: 3Nov 2024: 2Dec 2024: 2Jan 2025: 3Feb 2025: 5Apr 2025: 1Jun 2025: 1Aug 2025: 1Sep 2025: 1Oct 2025: 2Nov 2025: 2Dec 2025: 2Jan 2026: 22022202320242025
Cat7 · peak 1
May 2021: 1Sep 2023: 1May 2024: 1Aug 2024: 1Mar 2025: 1Feb 2026: 1Mar 2026: 12022202320242025
Horse0 · peak 1
2022202320242025
Other30 · peak 4
Apr 2021: 1Feb 2022: 1Mar 2022: 1May 2022: 3Aug 2022: 1Sep 2022: 1Jan 2023: 1Mar 2023: 1Apr 2023: 2Jul 2023: 1Mar 2024: 1Apr 2024: 1Dec 2024: 1Mar 2025: 1Apr 2025: 2Aug 2025: 4Sep 2025: 3Oct 2025: 1Nov 2025: 1Dec 2025: 1Jan 2026: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

049971987: 219871988: 51989: 41990: 61991: 219911992: 11993: 31994: 31995: 419951996: 51997: 81998: 101999: 4619992000: 502001: 402002: 582003: 9720032004: 802005: 952006: 902007: 8520072008: 612009: 532010: 482011: 3120112012: 222013: 222014: 92015: 2020152016: 212017: 192018: 272019: 2220192020: 102021: 112022: 172023: 3020232024: 302025: 322026: 5

2026 covers reports received through March 2026 only.

Signs listed in reports

share of tylosin reports listing the termall dog reports

  1. Death14.9%177
  2. Accidental exposure[exposure that was not intended]14%166
  3. Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]13.4%159
  4. Unclassifiable adverse event[event that fits no dictionary term]12.8%152
  5. Diarrhoea[diarrhea]7.9%94
  6. Anorexia[not eating]5.4%64
  7. Lack of efficacy - NOS[the product did not have the expected effect]5%59
  8. Injection site pain[pain where the injection was given]4.2%50
  9. Vomiting3.9%46
  10. Injection site swelling[swelling where the injection was given]3.2%38
  11. Depression[dull, quiet or withdrawn]3.1%37
  12. Unpalatable[legacy FDA term: the animal would not take it]3.1%37
  13. Lethargy[unusually tired or inactive]3%35
  14. Death by euthanasia[the animal was euthanized]2.9%34
  15. No sign[no clinical sign was reported]2.6%31
  16. Recumbency[lying down and unable or unwilling to rise]2.5%30
  17. Lameness1.9%22
  18. Sensory abnormality NOS[NOS: not otherwise specified]1.9%22
  19. Pruritus[itching]1.8%21
  20. Dyspnoea[difficulty breathing]1.7%20
  21. Hypersalivation[drooling]1.7%20
  22. Rash1.6%19
  23. Seal, Abnormal[a product quality report, not a sign in an animal]1.6%19
  24. Ataxia[unsteady, uncoordinated movement]1.5%18
  25. Behavioural disorder NOS[behaviour change, type not specified]1.5%18
  26. Bloody diarrhoea[diarrhea with blood]1.5%18
  27. Digestive tract disorder NOS[digestive problem, type not specified]1.4%17
  28. Injection site bleeding[bleeding where the injection was given]1.4%17

Top 30 of 630 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal5.7%68
Recovered with Sequela0.3%4
Ongoing6%71
Died20.1%238
Euthanized1.7%20
Outcome Unknown9%106

What kind of report it was

Safety issue82.9%982
Lack of expected effectiveness2.1%25
Both safety and lack of expected effectiveness3.2%38
Manufacturing or product defect11.7%139
Other0%0

Coloured bar: reports naming tylosin. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog24%284
Pig17.2%204
Human exposure17.1%202
Cattle14.9%177
Chicken5.2%61
Cat3.3%39

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year14.7%174
1 to 3 years7.6%90
4 to 7 years6.7%79
8 to 11 years7.7%91
12 years and over18.8%223
Age not given44.5%527

Weight of the animal

Under 5 kg (11 lb)8.8%104
5 to 9.9 kg (11–22 lb)6.1%72
10 to 24.9 kg (22–55 lb)7.2%85
25 to 44.9 kg (55–99 lb)8.3%98
45 kg and over (99 lb+)19.6%232
Weight not given50.1%593

Route of administration stated in reports: oral (509), intramuscular (166), subcutaneous (41), parenteral (33), topical (28), respiratory (inhalation) (17).

In context

MeasureTylosinAll dog reportsAll reports
Reports1,184985,6751,357,245
Share of that pool's reports naming this drug—0%0.1%
Classed serious, of reports stating it45.2%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports214.55563.8
Filed as lack of expected effectiveness (wholly or partly)5.3%—23%
Top term, share of reportsDeath 14.9%2.9%—

This set accounts for 90.8% of all reports naming tylosin, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Monensin + Tylosin790

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing tylosin (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
Tylan 200 Injection; Tylan 50 InjectionTylosinElanco US Inc.Cattle, SwineNADA 012-965
Tylovet 200 mg/mL InjectionTylosinHuvepharma EOODCattle, SwineNADA 138-955
BiloVetTylosinBimeda Animal Health Ltd.Cattle, SwineANADA 200-508
Formica Premix-T Medicatedapproval voluntarily withdrawnTylosinMountaire Feeds, Inc.—NADA 044-013
Ingmands Swine Premix-T Medicatedapproval voluntarily withdrawnTylosinThe Eugene Ingmand Co.—NADA 091-465
NSI Tylosin 10 Premixapproval voluntarily withdrawnTylosinNeese & Sons, Inc.—NADA 102-717
Tylan 10 Premix; Tylan 20 Premix; Tylan 40 Premix; Tylan 5 Premixapproval voluntarily withdrawnTylosinAgri-Basics—NADA 140-531

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about tylosin reports

How many adverse event reports has FDA received for tylosin?

1,184 reports record a drug with tylosin as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 27 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 7 approved applications with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

death (14.9%), accidental exposure (14%), lack of efficacy (bacteria) - NOS (13.4%), unclassifiable adverse event (12.8%) and diarrhoea (7.9%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (24%), pig (17.2%) and human exposure (17.1%). Among single-breed animals the most frequent labels are Holstein-Friesian, German Shepherd Dog, Domestic and Labrador Retriever; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

27 reports in the 12 months to March 2026, down 13% from 31 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that tylosin harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of tylosin?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.